A Varicella Outbreak in a School with High One-dose Vaccination Coverage, Beijing, China
Overview
Authors
Affiliations
Background: Varicella vaccine is available in the private sector in China, with a single dose currently recommended for children aged ≥12 months. We investigated a varicella outbreak in a school in Beijing with high varicella vaccination coverage to describe the outbreak, examine risk factors for vaccine failure, and calculate vaccine effectiveness.
Methods: A varicella case was defined as an acute generalized maculopapular rash without other apparent cause in a student without prior varicella attending the elementary school during August 30-December 28, 2010. Varicella among vaccinated students (breakthrough varicella) was defined as varicella occurring >42 days after vaccination. Students' vaccination status was verified with immunization records and clinical presentations were collected from health care practitioners.
Results: Of the 951 students, 934 (98%) had no prior varicella history. Among these students, 916 had received 1 dose of varicella vaccine and 2 had received 2 doses (98% vaccination coverage) before the outbreak. A total of 87 cases occurred during the outbreak; most had breakthrough varicella (86/87, 99%) and mild disease (83/87, 95%). Age at vaccination (<15 months vs. ≥15 months) and time since vaccination before outbreak (<5 years vs. ≥5 years) were not associated with development of breakthrough varicella. Single-dose varicella vaccination was 89% effective in preventing any varicella and 99% in preventing moderate/severe varicella.
Conclusion: Single-dose varicella vaccination is highly effective in reducing varicella incidence and mitigating disease severity, but not high enough to prevent outbreak. A two-dose program might help to prevent varicella outbreaks in Beijing.
Cao Z, Zhao D, Shi R, Zhao Y, Wen X, Ma Y Vaccines (Basel). 2024; 12(10).
PMID: 39460350 PMC: 11512427. DOI: 10.3390/vaccines12101184.
Varicella vaccine effectiveness evaluation in Wuxi, China: A retrospective cohort study.
Xiu S, Xu Z, Wang X, Zhang L, Wang Q, Yang M Epidemiol Infect. 2024; 152:e105.
PMID: 39344904 PMC: 11450501. DOI: 10.1017/S095026882400102X.
Li Y, Xu F, Liu M, Teng S, Liang F, Wang F Front Public Health. 2024; 12:1320407.
PMID: 38894987 PMC: 11183296. DOI: 10.3389/fpubh.2024.1320407.
Sun X, Dai C, Wang K, Liu Y, Jin X, Wang C Trop Med Infect Dis. 2023; 8(1).
PMID: 36668924 PMC: 9861499. DOI: 10.3390/tropicalmed8010017.
Lin M, Wang Q, Deng P, Xiao S, Fei Y, Xue C Hum Vaccin Immunother. 2022; 18(7):2143176.
PMID: 36509511 PMC: 9766464. DOI: 10.1080/21645515.2022.2143176.